Status:
ACTIVE_NOT_RECRUITING
ICIs with and Without MWA in Advanced Hepatocellular Carcinoma
Lead Sponsor:
The First People's Hospital of Neijiang
Conditions:
HCC
Therapy Adverse Effect
Eligibility:
All Genders
19-80 years
Brief Summary
Immunotherapy has become the main treatment recommendation for HCC. MWA treatment induces peripheral immune response, which may enhance the effectiveness of immunotherapy for advanced HCC. This study ...
Detailed Description
Research Title: Comparing the Efficacy of ICIs with and without MWA in Advanced Hepatocellular Carcinoma in Real Clinical Practice Background: Immunotherapy has become the main treatment recommendatio...
Eligibility Criteria
Inclusion
- Gender is not limited, age range is 19-80 years old.
- Meets the clinical diagnostic criteria for HCC.
- Progress after first-line treatment.
- CNLC staging: Stage IIa, IIb, or IIIb of advanced HCC.
- Child Pugh liver function grading score 5-7 points.
- The ECOG (Eastern Cooperative Oncology Group) score ranges from 0 to 1.
- The patient has a certain degree of compliance with the treatment plan and follow-up performance.
- For patients infected with hepatitis B, antiviral treatment with anti hepatitis B virus drugs should be carried out before receiving treatment; And the hepatitis B DNA titer of the patient was less than 10\^2 IU/ml.
Exclusion
- It has been determined that the inclusion criteria cannot be met.
- Enhanced CT or MRI shows more than 3 active lesions in the liver, and the shortest diameter of a single lesion is greater than 3cm.
- There is a portal vein cancer thrombus present.
- The extrahepatic metastatic lesions have not been well controlled.
- Other treatments were received during the process of receiving immunotherapy or immunotherapy combined with MWA treatment.
- There is active bleeding present.
- There are interstitial lung diseases, pulmonary fibrosis, and autoimmune diseases present.
Key Trial Info
Start Date :
January 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2025
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT06581497
Start Date
January 1 2023
End Date
January 1 2025
Last Update
January 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First People's Hospital of Neijiang City
Neijiang, Sichuan, China, 641000